CUE vs KEYS · rev $9.3M vs P/E 57, rev $4.98B
Cue Biopharma (CUE) versus Keysight Technologies Inc (KEYS) — a side-by-side from cached financials, not a winner call.
Cue Biopharma (CUE) is a biotechnology company listed on US.
Keysight Technologies Inc (KEYS) is a scientific & technical instruments company listed on US.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
Latest reported KEYS revenue for 2024-10-31 was $4.98B. Net income was $614.0M. Revenue was down 8.9% from 2023-10-31 to 2024-10-31. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.
CUE currently screens at market cap $59.5M. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.
Not investment advice. Open the CUE and KEYS stock pages for the full models.
Not investment advice.